Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Completed
Novo Nordisk A/S
Phase 2
2005-01-01
This trial is conducted in Europe. The trial is designed to show the effect of treatment with
liraglutide or placebo on blood glucose control after 14 weeks in subjects with type 2
diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The
trial is a multi-national trial with treatment concealed to participating subjects,
investigators and the sponsor. Treatment allocation is random with equal chance of being
assigned to each group.
Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes
Completed
Novo Nordisk A/S
Phase 2
2005-01-01
This trial is conducted in Japan. The aim of this research trial is to evaluate the effect of
treatment with liraglutide or placebo on blood glucose control after 14 weeks in Japanese
subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily
in the evening. The trial is a multi-national trial with treatment concealed to participating
subjects, investigators and the sponsor. Treatment allocation is random with equal chance of
being assigned to each group.
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
Terminated
Novo Nordisk A/S
Phase 3
2006-02-01
This trial is conducted in North America (the United States of America (USA) and Mexico).
The trial is designed to evaluate the effects of treatment with liraglutide versus
glimepiride in subjects with type 2 diabetes. The trial is a 52-week randomised, double-blind
trial period plus a 52-week open-label extension (week 104) followed by an additional
156-week continued open-label extension. The total duration of the treatment period is
planned to be 260 weeks (5 years).
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Completed
Novo Nordisk A/S
Phase 3
2006-05-01
This trial is conducted globally (the United States of America excepted). This trial is
designed to show the effect of treatment with liraglutide when added to existing glimepiride
therapy and to compare this to both glimepiride monotherapy and to rosiglitazone as add-on
therapy to glimepiride.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
